Drugmaker Valeant raises profit forecast; shares spike
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/19/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Medifast launches Trilivy, replacing its Optavia brand
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Adobe has received a takeover approach by a Big Tech company - Betaville
RBC Capital Comments on Valeant (VRX) Earnings
May 9, 2017 10:29 AM EDTRBC Capital maintains Sector Perform Valeant Pharmaceuticals (NYSE: VRX).
Analyst Douglas Miehm comments to clients that his team requires more details relating to Branded Rx revenues even though most investors seem to "find comfort in the Adj. EBITDA guidance increase." He closes... More
